Investment Rating - The investment rating for the company is maintained as "Buy" [1][10]. Core Views - The report highlights that the company's net interest income growth is improving, with a stable recovery in interest margins, which supports the resilience of its performance [6][7]. - The company has a robust strategy in place, with a three-year shareholder return plan approved by the board, indicating a commitment to returning value to shareholders [6]. - The report projects a target price of HKD 52.79, reflecting an increase from the previous target price of HKD 45.59, based on a target price-to-book (PB) ratio of 1.47 for 2026 [10]. Financial Performance Summary - For the fiscal year 2025, the company is expected to achieve a revenue of HKD 77,019 million, representing an 8.09% year-on-year growth [5][17]. - The net profit attributable to shareholders for 2025 is projected to be HKD 40,121 million, with a growth rate of 4.94% [5][17]. - The non-performing loan (NPL) ratio is expected to stabilize at 1.14% for 2025, with a provision coverage ratio of 96% [9][17]. - The report anticipates a steady increase in earnings per share (EPS) from HKD 3.79 in 2025 to HKD 5.19 by 2028 [5][17]. Asset Quality and Cost Control - The company has maintained a solid asset quality, with a year-end NPL ratio of 1.14% and a credit cost of 0.49% for 2025, indicating effective risk management [9][17]. - The cost-to-income ratio is projected to be 23.6% for 2025, showing continued efficiency in cost control [9][17]. - The core Tier 1 capital adequacy ratio is expected to be 24.01% at the end of 2025, reflecting a strong capital position [9][17].

Investment Rating - The report maintains an "Accumulate" rating for A shares and a "Buy" rating for H shares [7] Core Insights - The company achieved a record high revenue of 28.3 billion RMB in 2025, up 24% year-on-year, and a net profit of 12.5 billion RMB, up 25% year-on-year, although it fell short of expectations due to market volatility in Q4 [1][2] - The total assets reached 855.7 billion RMB, marking a 16% year-on-year increase, with a year-end leverage ratio of 4.28x, indicating a more aggressive use of leverage [2] - The company has adjusted its asset allocation, increasing equity investments while reducing fixed income investments, aligning with the anticipated recovery of the stock market in 2025 [3] Summary by Sections Financial Performance - The investment business generated 13.1 billion RMB in revenue, accounting for approximately 46% of total revenue, while brokerage income surged by 43% year-on-year to 8.8 billion RMB [4] - The net income from credit business rose by 16% year-on-year to 4.5 billion RMB, reflecting a steady increase in margin financing and customer deposits [4] Profit Forecast and Valuation - The company expects net profits of 14.5 billion RMB, 15.9 billion RMB, and 17.4 billion RMB for 2026, 2027, and 2028 respectively, with a downward adjustment of 15% and 18% for 2026 and 2027 [5] - The target price is set at 17.33 RMB for A shares and 13.07 HKD for H shares, reflecting a premium valuation based on expected steady growth and competitive improvement [5]

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7] Core Views - The company reported a revenue of 1,029.784 billion RMB for 2025, a year-on-year decrease of 3.50%, and a net profit attributable to shareholders of 18.363 billion RMB, down 17.34% year-on-year [1] - The company is shifting towards high-quality development, focusing on asset consolidation, cost optimization, and improving operational quality, which is beginning to show results [1] - The real estate business continues to be a drag, while international operations have shown significant improvement, with overseas new contracts signed amounting to 363.3 billion RMB, a year-on-year increase of 16.46% [2] Summary by Sections Financial Performance - In 2025, the company achieved revenues of 9,067 billion RMB in engineering contracting, 169 billion RMB in design consulting, 244 billion RMB in industrial manufacturing, 666 billion RMB in real estate development, and 746 billion RMB in material logistics, with only industrial manufacturing showing growth [2] - The overall gross margin decreased to 9.72%, down 0.55 percentage points year-on-year, with the real estate sector experiencing a decline in gross margin [2] Cash Flow and Expenses - The operating cash flow for the year was 2.957 billion RMB, indicating a positive turnaround, although collection pressures remain [3] - The company’s expense ratio for the year was 5.94%, slightly up by 0.05 percentage points year-on-year, with total expenses decreasing by 2.7% [3] Dividend and Future Plans - The company plans to distribute a cash dividend of 3 RMB per share for 2025, with a dividend payout ratio of 25.5%, resulting in an estimated dividend yield of approximately 4.3% for A shares [4] - For 2026, the company aims for a new contract target of 30,000 billion RMB and revenue of 10,016 billion RMB, while controlling costs and taxes at 9,720 billion RMB [4] Profit Forecast and Valuation - The adjusted net profit forecast for 2026-2028 is 17.3 billion RMB, 17.2 billion RMB, and 17.6 billion RMB respectively, with corresponding EPS of 1.27, 1.26, and 1.29 RMB [5] - The target price for A shares is set at 8.89 RMB and for H shares at 6.47 HKD, based on a valuation of 7x and 4.5x PE for 2026 [5]

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Insights - The company reported a revenue of 6.67 billion RMB for 2025, representing a year-over-year increase of 14.9% (16.8% at constant exchange rates), and a net profit attributable to shareholders of 1.13 billion RMB, up 19.4% year-over-year [1][2]. - The company expects a revenue growth of 19%-22% for the full year of 2026, driven by a strong order backlog of 1.385 billion USD, which is a 31.7% increase year-over-year [1][5]. - Emerging businesses, particularly in chemical and biological macromolecules, have shown rapid growth, with revenues increasing by 57.3% year-over-year [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 42.0% in 2025, a slight decrease of 0.4 percentage points year-over-year. The sales, management, and R&D expense ratios were 3.2%, 11.5%, and 8.9%, respectively, all showing a decrease year-over-year due to cost reduction initiatives [2]. - Operating cash flow for 2025 was 1.408 billion RMB, reflecting a 12.2% increase year-over-year, indicating improved cash flow levels [2]. Emerging Business Growth - Revenue from emerging businesses reached 1.929 billion RMB, with international revenue growing over 240%. The segment's gross margin improved to 30.1%, up 8.5 percentage points year-over-year [3]. - Specific highlights include: - Chemical macromolecules revenue of 1.028 billion RMB, up 123.7% year-over-year, with a significant increase in order backlog [3]. - Biological macromolecules revenue of 294 million RMB, up 95.8% year-over-year, with new production capacity expected to come online [3]. Core Business Development - The small molecule CDMO segment generated 4.735 billion RMB in revenue, a 3.6% increase year-over-year, with a total of 515 projects delivered [4]. - The company anticipates 16 small molecule PPQ projects in 2026, indicating a robust pipeline and commercial order reserves [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is 1.42 billion, 1.84 billion, and 2.23 billion RMB, respectively, with adjustments reflecting a positive outlook on order levels and cost efficiency [5]. - The company is valued at 37x PE for A shares and 29x PE for H shares for 2026, with target prices set at 145.61 RMB and 129.44 HKD, respectively [5].

Investment Rating - The report has downgraded the investment rating of the company to "Accumulate" [5][6]. Core Views - The company's revenue for 2025 reached 14.41 billion RMB, a year-on-year increase of 24.86%, while the net profit attributable to shareholders was 0.472 billion RMB, up 9.60% year-on-year. However, the net profit fell short of expectations due to rising storage prices, increased raw material costs, and foreign exchange losses [1][5]. - The company maintains a strong position in the laptop battery sector and is accelerating the introduction of mobile phone batteries to major clients like Apple. Adjustments in accounting depreciation policies have released profits, but the impact of rising storage prices on consumer battery demand and increased costs have led to a revision in revenue growth expectations [5][6]. Summary by Sections Financial Performance - In Q4 2025, the company reported revenue of 4.089 billion RMB, a year-on-year increase of 35.2% but a quarter-on-quarter decrease of 3.2%. The net profit attributable to shareholders was 0.085 billion RMB, down 47.8% year-on-year and 68.6% quarter-on-quarter [2]. - The company shipped approximately 100 million consumer battery cells in Q4, with a net profit per cell of about 1.3-1.4 RMB. The decline in profitability was attributed to reduced demand due to storage price increases and rising raw material costs [2]. Business Segments - In the consumer battery segment, the company achieved revenue of 6.341 billion RMB in laptop products, remaining stable year-on-year, with a sales volume increase of 2.5%. In mobile phone products, revenue reached 4.493 billion RMB, up 38.2% year-on-year, with a sales volume increase of 42.0% [11]. - The company's dynamic storage business, particularly in automotive and drone applications, saw significant growth, with revenue from the Zhejiang subsidiary reaching 2.265 billion RMB, a year-on-year increase of 130.7%. The company has secured contracts with major automotive manufacturers and maintained deep cooperation with clients like DJI in the drone sector [4][11]. Profitability and Forecasts - The report anticipates a downward revision of the company's net profit forecasts for 2026 and 2027 to 0.820 billion RMB and 1.069 billion RMB, respectively, reflecting a reduction of 50% and 51% from previous estimates [5][14]. - The expected average PE ratio for comparable companies in 2026 is 18 times, while the company is assigned a PE of 24 times for the same year, with a target price set at 17.28 RMB, down from 35.04 RMB [5][14].

Investment Rating - The report maintains a "Buy" rating for both A and H shares of the company [7] Core Insights - The company achieved a revenue of 1.658 billion RMB and a net profit attributable to shareholders of 298 million RMB in 2025, reflecting a year-over-year change of -17.9% and +302.1% respectively, aligning with performance forecasts [1] - The company has seen a significant increase in new order amounts, with 4Q25 new orders reaching 960 million RMB, a year-over-year increase of 118.2%, indicating a recovery in domestic industry demand [1] - The company’s gross margin for 2025 was 20.7%, down 7.7 percentage points year-over-year, primarily due to the impact of low-quality orders from previous periods [2] - Operating cash flow improved significantly, with a net cash flow of 445 million RMB in 2025, up 31.2% year-over-year [2] - The company is expanding its technical capabilities, with a notable increase in project signings for antibody, small nucleic acid, ADC, and peptide drugs [3] - The overseas revenue reached 453 million RMB, accounting for 27.3% of total revenue, reflecting a year-over-year increase of 3.3% [4] - The company expects a recovery in domestic business in 2026, driven by improved market competitiveness and ongoing demand recovery [4] Summary by Sections Financial Performance - In 2025, the company reported a revenue of 1.658 billion RMB, a decrease of 17.87% from the previous year, while net profit attributable to shareholders was 298 million RMB, an increase of 302.08% [10] - The company forecasts net profits of 528 million RMB, 654 million RMB, and 848 million RMB for 2026, 2027, and 2028 respectively, with significant upward adjustments of 54% and 48% for 2026 and 2027 [5][11] Business Development - The company’s total order backlog was approximately 2.6 billion RMB, with new orders also around 2.6 billion RMB, indicating a year-over-year increase of 41.3% [1] - The company is enhancing its core business capabilities and expanding its facilities, which will support future business development [3] Market Outlook - The report anticipates continued growth in overseas revenue and a gradual recovery in domestic business, supported by the company’s strong market position in non-clinical safety evaluation [4] - The target prices for A and H shares are set at 45.83 RMB and 28.79 HKD respectively, based on a price-to-earnings ratio of 65x and 36x for 2026 [5]

Investment Rating - The report maintains an investment rating of "Buy" for the company with a target price of HKD 98.59 [1]. Core Insights - The company reported a revenue of USD 370.28 million for 2025, representing a year-over-year increase of 37.8%, and a net profit of USD 28.44 million, up 135% year-over-year, exceeding consensus expectations [6][9]. - The growth in revenue is attributed to the increase in case numbers in both domestic and overseas markets, with a total case count of 532,000, reflecting a 48% year-over-year growth [6][7]. - The company is expected to achieve a revenue growth of 22% and an adjusted net profit growth of 32% in 2026, driven by continued expansion in both domestic and international markets [6][8]. Summary by Sections Financial Performance - For 2025, the company achieved a revenue of USD 370.28 million and a net profit of USD 28.44 million, with adjusted net profit reaching USD 43.77 million [5][6]. - The revenue growth is primarily driven by the expansion of case numbers in the domestic market, which saw a 10.1% increase to USD 207 million, and a significant 102.5% increase in overseas revenue to USD 163 million [7][8]. Domestic Business - The domestic market generated USD 207 million in revenue, with a case count of 276,000, up 26.3% year-over-year [7]. - The company is focusing on penetrating lower-tier cities and enhancing brand credibility through initiatives like the Angel Care program, which is expected to drive further market share growth [7]. Overseas Business - The overseas market revenue reached USD 163 million, with a case count of 256,000, reflecting an 82.1% year-over-year increase [8]. - The company anticipates continued high growth in overseas revenue, with expectations to reach 340,000 cases in 2026, supported by improved brand reputation and clinical experience [8]. Profitability Forecast - The adjusted EPS for 2026 is projected to be USD 0.34, with a target PE ratio of 37 times, leading to a target price of HKD 98.59 [9][10]. - The report indicates an upward revision in revenue forecasts due to strong overseas case growth and improved domestic market share [10][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 98.59 [1][6]. Core Insights - The company reported a revenue of USD 370.28 million for 2025, representing a year-over-year increase of 37.8%, and a net profit of USD 28.44 million, up 135% year-over-year, exceeding consensus expectations [6][9]. - The growth in revenue is attributed to the expansion of case numbers in the domestic market due to grassroots market development and increased market share, as well as a rise in overseas case numbers driven by brand recognition [6][7]. - The company is expected to achieve a revenue growth of 22% year-over-year in 2026, with adjusted net profit projected to grow by 32% [6][9]. Summary by Sections Financial Performance - For 2025, the company achieved a revenue of USD 370.28 million and a net profit of USD 28.44 million, with adjusted net profit at USD 43.77 million [5][6]. - The total number of cases reached 532,000, marking a 48% year-over-year increase [6][8]. Domestic Business - The domestic market generated USD 207 million in revenue for 2025, a 10.1% increase year-over-year, with case numbers growing to 276,000, up 26.3% year-over-year [7][8]. - The company anticipates reaching 325,000 cases in 2026, representing an 18% year-over-year increase, driven by deeper penetration into lower-tier cities and the introduction of early orthodontic products [7][8]. Overseas Business - The overseas market generated USD 163 million in revenue for 2025, a significant 102.5% increase year-over-year, with case numbers climbing to 256,000, up 82.1% year-over-year [8][9]. - The company expects to achieve monthly profitability by the end of 2026, supported by improved operational efficiency and the launch of international products [8][9]. Profitability Forecast and Valuation - The adjusted EPS for 2026 is projected at USD 0.34, with a target price based on a 37x PE ratio, aligning with comparable companies [9][11]. - The report indicates an upward revision in revenue forecasts due to strong overseas case growth and improved domestic market share [9][11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 23.40 and HKD 19.25 [7] Core Insights - The company reported a total revenue of RMB 35.493 billion for 2025, representing a year-on-year increase of 30.49%, and a net profit attributable to shareholders of RMB 13.702 billion, up 42.18% year-on-year [11] - The financial investment scale expanded significantly, with total assets reaching RMB 975.484 billion, a 29% increase from the beginning of the year, and financial investments amounting to RMB 483.335 billion, up 31% [2] - The brokerage segment saw net income of RMB 9.597 billion, a 44% increase year-on-year, with a market share of approximately 4.05% in stock trading [3] - Asset management income grew steadily to RMB 7.703 billion, contributing 21.7% to total revenue, while investment banking revenue increased by 14% to RMB 8.84 billion [4] - The company expects net profit attributable to shareholders to reach RMB 15.720 billion in 2026, with a projected BPS of RMB 21.27 [5] Summary by Sections Financial Performance - For 2025, the company achieved total revenue of RMB 35.493 billion and a net profit of RMB 13.702 billion, with respective year-on-year growth rates of 30.49% and 42.18% [11] - The fourth quarter net profit was RMB 2.767 billion, reflecting a quarter-on-quarter decrease of 38% [1] Investment and Brokerage - The financial investment scale reached RMB 483.335 billion, a 31% increase from the start of the year, with stock TPL and OCI growing by 63% and 114% respectively [2] - Brokerage net income was RMB 9.597 billion, with a significant increase in stock trading volume, achieving a market share of 4.05% [3] Asset Management and Investment Banking - Asset management net income was RMB 7.703 billion, contributing 21.7% to total revenue, while investment banking revenue rose to RMB 8.84 billion [4] - The company successfully completed multiple IPO projects and increased its bond underwriting significantly, with domestic bond issuance reaching RMB 3.189 trillion [4] Profit Forecast and Valuation - The forecast for net profit attributable to shareholders is RMB 15.720 billion for 2026, with a projected BPS of RMB 21.27 and a target valuation of 1.1x PB for A shares and 0.8x PB for H shares [5]

Investment Rating - The report maintains a "Buy" rating for both A and H shares of the company [7] Core Views - The company achieved revenue and net profit of 1.658 billion and 298 million RMB in 2025, reflecting a year-over-year change of -17.9% and +302.1% respectively, aligning with performance forecasts [1] - The company has seen a significant increase in new orders, with 4Q25 new signed orders amounting to 960 million RMB, a year-over-year increase of 118.2%, indicating a recovery in domestic demand [1] - The overall order backlog for the company stands at approximately 2.6 billion RMB, up 18.2% year-over-year, with new signed orders also increasing by 41.3% year-over-year [1] Summary by Relevant Sections Financial Performance - The company's gross margin for 2025 was 20.7%, down 7.7 percentage points year-over-year, primarily due to the impact of low-quality orders from previous periods [2] - Operating cash flow for 2025 was 445 million RMB, reflecting a significant improvement of 31.2% year-over-year [2] Business Segments - Non-clinical research services generated revenue of 1.577 billion RMB, down 17.8% year-over-year, while overseas revenue in this segment grew by 3.1% [3] - Clinical services and others reported revenue of 72.83 million RMB, down 27.1% year-over-year, but the company is advancing its capabilities in biomarker detection for neurological diseases [3] - The experimental model supply segment saw a remarkable increase in revenue to 7.75 million RMB, up 754.5% year-over-year, indicating strong demand for diverse research needs [3] Geographic Revenue Breakdown - Overseas revenue reached 453 million RMB, up 3.3% year-over-year, accounting for 27.3% of total revenue, an increase of 5.6 percentage points year-over-year [4] - Domestic revenue was 1.204 billion RMB, down 23.8% year-over-year, primarily due to pressure from historical low-quality orders [4] Profit Forecast and Valuation - The company expects net profit attributable to shareholders to be 528 million, 654 million, and 848 million RMB for 2026, 2027, and 2028 respectively, with significant upward adjustments of 54% and 48% for 2026 and 2027 [5][11] - The report assigns a price-to-earnings ratio of 65x for A shares and 36x for H shares for 2026, with target prices set at 45.83 RMB and 28.79 HKD respectively [5]